Pyxis Oncology (PYXS) 2025 Conference Transcript

Summary of Pyxis Oncology (PYXS) 2025 Conference Call Company Overview - Company: Pyxis Oncology - Focus: Development of antibody-drug conjugates (ADCs) - Lead Asset: Nykbo, targeting extracellular domain b (EDB), a splice variant of fibronectin, expressed in various solid tumors with minimal expression in normal tissues [2][3] Clinical Development and Data - Clinical Trials: Nykbo is currently in clinical trials for both monotherapy and combination therapy with pembrolizumab (Keytruda), particularly in head and neck cancers [3][30] - Phase 1 Data: - Significant tumor regression observed in six out of nine tumor types tested, with a confirmed overall response rate (ORR) of 50% and a 100% disease control rate in head and neck cancer [4][5] - The data was based on a cohort of six patients at a therapeutic dose range of 3.6 to 5.4 mg/kg [4] - The median time on therapy for head and neck patients was approximately 16 weeks, compared to the average of 65-70 days typically seen in Phase 1 studies [13] Competitive Landscape - Market Dynamics: The head and neck cancer treatment landscape has become competitive with the introduction of bispecific antibodies targeting EGFR, such as those from Merus and Vicara [5][6] - Comparative Efficacy: - Pyxis's 50% confirmed ORR in head and neck cancer is higher than Merus's 37% and Vicara's 0% in their respective Phase 1 trials [5][6] - Pyxis has observed responses in patients resistant to prior treatments, indicating a potential niche for Nykbo [6][7] Patient Enrollment and Characteristics - Enrollment Criteria: The expansion cohort is focusing on second and third-line treatment patients, contrasting with the heavily pretreated patients in the initial Phase 1 trial [16][18] - Patient Characteristics: The median number of prior treatment lines for the initial cohort was four, while the current expansion targets patients with fewer prior treatments [16][18] Safety Profile - Adverse Events: The safety profile of Nykbo appears favorable compared to other ADCs, with no significant grade 3 or 4 neuropathies or ocular toxicities observed [25][40] - Grade 5 Event: A grade 5 non-treatment-related event occurred in a patient with multiple comorbidities, which was not attributed to the drug [28] Future Data Expectations - Upcoming Data Releases: - Data from the monotherapy cohort is expected in the second half of the year, focusing on 20 patients in two arms: one for PD-1 and platinum-resistant patients and another for EGFR and PD-1 resistant patients [30][31] - Preliminary data from the combination study with pembrolizumab is also anticipated in the second half of the year [32][45] Strategic Priorities - Execution Focus: The company emphasizes execution in patient enrollment, data generation, and analytics as its top priorities [56] Additional Insights - Mechanism of Action: The ADC's mechanism includes direct tumor killing, bystander effects, and immunogenic cell death, which may synergize well with pembrolizumab [43] - Market Positioning: Pyxis aims to carve out a niche in the evolving treatment landscape, particularly in segments not fully addressed by current competitors [31][55]